Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979178 | 0.77 | METAP1 (0.39) | AURKARPS6KB1 | |
| SCHEMBL16963126 | 0.75 | LMNA (0.40) | AAK1LMNANPC1RAB9AMAPK1 | |
| SCHEMBL14979177 | 0.71 | AKT1 (0.41) | AURKARPS6KB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5465531 | 0.71 | HPGD (0.44) | AAK1EGLN2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31565018 | 0.71 | HPGD (0.44) | AAK1EGLN2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20901331 | 0.70 | METAP1 (0.44) | NPC1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL22601392 | 0.70 | HTR1A (0.35) | LMNAEGLN2SMN1; SMN2 | |
| SCHEMBL16963451 | 0.69 | PTGDR2 (0.46) | LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL14979175 | 0.69 | METAP1 (0.44) | AURKARPS6KB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22601390 | 0.68 | PTGDR2 (0.36) | AAK1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339522-A1 | PHENOXYMETHYL DERIVATIVES | CNKSR1, RB1, RCOR1 | AAK1 3659/4885LMNA 2843/4885EGLN2 1285/4885 |
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | AAK1 3659/4885LMNA 2843/4885EGLN2 1285/4885 |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | AAK1 2569/4885LMNA 645/4885EGLN2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.